Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting
28 April 2021 - 6:35AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced the
presentation of new data from its CRISPR/Cas9 platform at the 24th
American Society of Gene & Cell Therapy (ASGCT) Annual Meeting,
taking place virtually from May 11-14, 2021.
“The data accepted for presentation at ASGCT reflects our
ongoing commitment to finding new ways to treat and potentially
cure a variety of diseases. Utilizing our modular in vivo insertion
technology, we demonstrate the potential to durably restore normal
AAT protein levels after a single dose. We continue to advance
multiple genome editing strategies for patients living with AATD,”
said President and Chief Executive Officer John Leonard, M.D. “In a
separate presentation, Intellia will share our integrative genomics
approach that combines computational, biochemical and cell-based
genome-wide off-target discovery as well as characterization of
potential DNA structural variants to identify precise CRISPR/Cas9
sequences that are safe human therapeutic candidates.”
ASGCT Annual Meeting Presentations & Invited
Sessions
Oral Presentation:
Title: “CRISPR/Cas9-Mediated Targeted Gene
Insertion Platform Achieves Durable, Normal Human Alpha-1
Antitrypsin Protein Levels in Non-Human Primates”Abstract
number: 15Session Title: Delivery
Technologies and CRISPR for TherapeuticsSession
Room: Room 3Date and Time: Tuesday, May
11, 2021, 5:30 – 5:45 p.m. ETPresenting Author:
Sean Burns M.D., vice president of Intellia’s Disease Biology and
Pharmacology group
Invited Talks:
Title: “Characterization of Potential
Unintended Genome Editing with CRISPR/Cas9 for New Therapeutics”
Session Type: Pre-Meeting Program Session
Title: Moving Genome Editing to the Clinic: from
Technology to Therapeutics Date and Time: Monday,
May 10, 2021, 1:05 – 1:30 p.m. ET Presenting
Author: Daniel O’Connell Ph.D., director of Intellia’s
platform development group
Title: “Development of Systemic CRISPR-Based
Therapeutics”Session Title: Genome Editing –
Clinical and Preclinical UpdatesDate and Time:
Tuesday, May 11, 2021, 10:26 – 10:52 a.m. ET Presenting
Author: Laura Sepp-Lorenzino, Ph.D., chief scientific
officer
Additional data collected will be included in final meeting
presentations. All abstracts for the ASGCT Annual Meeting are
available on ASGCT’s website here.
About Intellia TherapeuticsIntellia
Therapeutics is a leading clinical-stage genome editing company,
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
both producing therapeutics that permanently edit and/or correct
disease-associated genes in the human body with a single
administration, and creating enhanced engineered cells that can
treat oncological and immunological
diseases. Intellia’s combination of deep
scientific, technical and clinical development
experience, along with its leading intellectual property portfolio,
puts it in a unique position to unlock broad therapeutic
applications of the CRISPR/Cas9 technology and create new classes
of therapeutic products. Learn more about Intellia and CRISPR/Cas9
at intelliatx.com. Follow us on Twitter @intelliatweets.
Forward-Looking Statement
This press release contains “forward-looking statements” of
Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements include, but are not limited
to, express or implied statements regarding Intellia’s beliefs and
expectations regarding its: plans to advance and complete
preclinical studies, including non-human primate studies, for its
AATD research program; development of a proprietary LNP/AAV hybrid
delivery system, as well as its modular platform to advance its
complex genome editing capabilities, such as gene insertion, as
well as knockout editing capabilities; advancement and expansion of
its CRISPR/Cas9 technology to develop human therapeutic products,
as well as its ability to maintain and expand its related
intellectual property portfolio; ability to demonstrate its
platform’s modularity and replicate or apply results achieved in
preclinical studies, including those its AATD research program, in
any future studies, including human clinical trials; and its
ability to develop other in vivo or ex vivo cell therapeutics of
all types using CRISPR/Cas9 technology.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: risks
related to Intellia’s ability to protect and maintain its
intellectual property position; risks related to Intellia’s
relationship with third parties, including its licensors and
licensees; risks related to the ability of its licensors to protect
and maintain their intellectual property position; uncertainties
related to the authorization, initiation and conduct of studies and
other development requirements for its product candidates; the risk
that any one or more of Intellia’s product candidates will not be
successfully developed and commercialized; and the risk that the
results of preclinical studies or clinical studies will not be
predictive of future results in connection with future studies. For
a discussion of these and other risks and uncertainties, and other
important factors, any of which could cause Intellia’s actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in Intellia’s
most recent annual report on Form 10-K as well as discussions of
potential risks, uncertainties, and other important factors in
Intellia’s other filings with the Securities and Exchange
Commission (“SEC”). All information in this press release is as of
the date of the release, and Intellia undertakes no duty to update
this information unless required by law.
Intellia Contacts:
Investors:Lina LiDirectorInvestor
Relations+1-857-706-1612lina.li@intelliatx.com
Media:Julie Ferguson Interim Head of External
Affairs &
Communications+1-312-385-0098julie.ferguson@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024